Virus-Like Particles as vaccine antigens and adjuvants: application to chronic disease, cancer immunotherapy and infectious disease preventive strategies
Gerardo Guillén(Hunan City University), Luís Herrera(Orlando Health), Verena Muzio(Centro de Ingeniería Genética y Biotecnología), Enrique V. Iglesias(Sorbonne Université), Mauricio Guzmán(Instituto de Medicina Tropical “Pedro Kourí”), Yadira Lobaina(Centro de Ingeniería Genética y Biotecnología), Eduardo Pentón(Centro de Ingeniería Genética y Biotecnología), Isis Torréns(Centro de Ingeniería Genética y Biotecnología), Julio Aguilar(Centro de Ingeniería Genética y Biotecnología), Jesús A. Junco(Centro de Ingeniería Genética y Biotecnología), Santiago Dueñas(Centro de Ingeniería Genética y Biotecnología), Lisset Hermida(Centro de Ingeniería Genética y Biotecnología)
Cited by 21
Related Papers
Epidermal growth factor in clinical practice – a review of its biological actions, clinical indications and safety implications
|International Wound Journal|2009|167
A novel cancer vaccine composed of human-recombinant epidermal growth factor linked to a carrier protein: Report of a pilot clinical trial
|Annals of Oncology|1998|155
Glucose Toxic Effects on Granulation Tissue Productive Cells: The Diabetics’ Impaired Healing
|BioMed Research International|2012|153
Wound Chronicity, Impaired Immunity and Infection in Diabetic Patients
|MEDICC Review|2021|139
Insulin Resistance at the Crossroad of Alzheimer Disease Pathology: A Review
|Frontiers in Endocrinology|2020|134